Evaluation of a New Blood Test for Detecting Multiple Types of Cancer Early

The SUMMIT Study is a prospective, observational, longitudinal, cohort study being conducted in London in the United Kingdom. It is designed to enroll approximately 25,000 men and women age 50 to 77 years who do not have a cancer diagnosis at the time of enrollment. SUMMIT aims to further evaluate GRAIL’s blood test designed to detect multiple types of cancer, including lung cancer.

The participants will be people at high risk of lung and other cancers due to a significant smoking history. Participants will be followed annually for three years and then will be followed for five years through national health registries as well as their medical records.

Current Status: Enrolling

Determining Feasibility of a Lung Screening Program

A low dose computed tomography (LDCT) scan is an imaging method that can be used to help detect lung cancer in people at high risk for the disease. Currently, LDCT is not widely available in the UK. In addition to evaluating the ability of a blood test to detect multiple cancer types, SUMMIT aims to assess the feasibility of implementing a lung cancer screening program in the United Kingdom.


  • University College London (UCL)
  • University College London Hospitals National Health Service (NHS) Foundation Trust (UCLH)


Eligible people will be invited to participate in the study from select locations in London in the United Kingdom. To be eligible, people must either currently smoke or have smoked regularly in the past and meet certain other criteria.

Visit Study on